Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Articles

Pages

8079 items
12:16 PM, Sep 14, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

MS Society protests NICE rejection of Ocrevus for primary progressive MS

The U.K.'s NICE issued a final appraisal determination (FAD) on Sept. 10 recommending against the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat primary progressive multiple sclerosis with imaging features characteristic of inflammatory...
10:28 AM, Sep 14, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

ICER finds opioid use disorder treatments not cost-effective

In a draft evidence report, ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines. The institute compared the clinical effectiveness and value of three...
11:42 AM, Sep 07, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Dermira launching Qbrexza for primary axillary hyperhidrosis

Dermira Inc. (NASDAQ:DERM) will launch Qbrexza glycopyrronium tosylate to treat primary axillary hyperhidrosis in patients ages nine and older on Oct. 1. The topical anticholinergic agent, which FDA approved in June, will be priced at...
11:01 AM, Sep 07, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Vertex finalizes Orkambi deal with Australia

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it reached an agreement Sept. 3 with the Australian government for the reimbursement of cystic fibrosis drug Orkambi lumacaftor/ivacaftor. The country will list the drug on its Pharmaceutical Benefits Scheme...
11:49 AM, Aug 31, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Gilead's Yescarta rebuffed by NICE, second orphan drug setback in August

One day after the European Commission approved CAR T therapy Yescarta axicabtagene ciloleucel from the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD), U.K.'s NICE published draft guidance recommending against the use of therapy....
11:18 AM, Aug 31, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Ono, BMS switching to flat dosing for Opdivo in Japan

In November, the unit price of cancer drug Opdivo nivolumab from Ono Pharmaceutical Co. Ltd. (Tokyo:4528) and partner Bristol-Myers Squibb Co. (NYSE:BMY) will decrease by 37.5% in Japan following a change from a weight-based dosage...
11:07 AM, Aug 31, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Alkermes, Oklahoma negotiating value-based Medicaid purchasing agreements

The Oklahoma Health Care Authority (OHCA) said it has signed its first contract to negotiate value-based Medicaid purchasing agreements with Alkermes plc (NASDAQ:ALKS) for schizophrenia drug Aristada aripiprazole lauroxil. OHCA is also close to agreements for...
11:59 AM, Aug 17, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

Vertex nears Orkambi reimbursement agreement with Australia

Australia's Pharmaceutical Benefits Advisory Committee (PBAC) recommended in July that the government subsidize the price of Orkambi lumacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). The drug is approved to treat cystic fibrosis in patients ages six...
8:46 PM, Aug 16, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

NICE draft guidance recommends against Biogen's Spinraza for SMA

U.K.’s NICE published draft guidance recommending against the use of Spinraza nusinersen from Biogen Inc. (NASDAQ:BIIB) to treat spinal muscular atrophy. The committee cited significant uncertainties around Spinraza's long-term benefits, as well as the drug's...
11:59 AM, Aug 10, 2018  |  BC Week In Review | Company News  |  Sales & Marketing

CAR Ts approved for new technology add-on payments

CMS approved new technology add-on payments (NTAPs) for CAR T cell therapies Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) and Yescarta axicabtagene ciloleucel from the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD). Through the...

Pages